# ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma

> **NCT03888859** · EARLY_PHASE1 · COMPLETED · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 12 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer
- Liver Neoplasms
- Metastatic Liver Cancer

## Interventions

- **BIOLOGICAL:** ET1402L1-ARTEMIS™ T cells -IV
- **BIOLOGICAL:** ET1402L1-ARTEMIS™ T cells -intra-hepatic artery
- **BIOLOGICAL:** ET1402L1-ARTEMIS™ T cells -Intratumoral Injections

## Key facts

- **NCT ID:** NCT03888859
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-06
- **Primary completion:** 2019-04-13
- **Final completion:** 2020-12-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888859, "ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03888859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*